Mercy BioAnalytics: Myla Lai-Goldman

Myla Lai-Goldman has been appointed to the board of directors of Mercy BioAnalytics, a company developing extracellular vesicle-based liquid biopsy tests for early cancer detection. Most recently, she was executive VP as well as chief medical and chief scientific officer at Laboratory Corporation of America, where she worked for more than 18 years. She is also a cofounder and chairperson of GeneCentric Therapeutics, where she was previously president and CEO. In addition, she is a venture partner at Hatteras Venture Partners and a managing partner at Personalized Science, a diagnostic consulting company. Lai-Goldman holds an MD from Columbia University College of Physicians and Surgeons.